Renal and Peripheral Hemodynamic Function in Patients With Type 1 Diabetes Mellitus
Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
Protein kinase C (PKC), an enzyme in the body, has been implicated in the process of diabetic
microvascular complications. The purpose of this study will be to evaluate the renal
hemodynamic and peripheral vascular effects of PKC inhibition with ruboxistaurin mesylate (an
inhibitor of PKC) in patients with Type 1 diabetes mellitus and evidence of early
nephropathy. In this pilot study, 21 patients with type 1 diabetes were planned to be
randomized to LY333531 or placebo in a 2:1 fashion, after an initial period of testing. After
8 weeks of study drug, patients were retested.